32,769 results match your criteria vaccine dose


Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients.

Am J Transplant 2021 Jul 31. Epub 2021 Jul 31.

Department of Nephrology and Organs Transplantation, Toulouse Rangueil University Hospital, Toulouse, France.

A weak humoral response to two-doses of SARS-CoV-2 vaccine was observed in solid organ transplant (SOT) patients (1,2). Preliminary reports suggested the usefulness of a boost with a third dose (3) (4). Herein, we report the humoral response in 396 SOT patients (mean age 59 ± 15 years, 65 % men) who were given 3 doses messenger RNA-based vaccine (BNT162b2 vaccine [Pfizer-BioNTech]) (Table S1). Read More

View Article and Full-Text PDF

Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice.

FEBS Lett 2021 Jul 31. Epub 2021 Jul 31.

MRC Laboratory of Molecular Biology, Cambridge, UK.

The COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, has triggered a worldwide health emergency. Here, we show that ferritin-like Dps from hyperthermophilic Sulfolobus islandicus, covalently coupled with SARS-CoV-2 antigens via the SpyCatcher system, forms stable multivalent dodecameric vaccine nanoparticles that remain intact even after lyophilisation. Immunisation experiments in mice demonstrated that the SARS-CoV-2 receptor binding domain (RBD) coupled to Dps (RBD-S-Dps) elicited a higher antibody titre and an enhanced neutralising antibody response compared to monomeric RBD. Read More

View Article and Full-Text PDF

COVID-19 after two doses of mRNA vaccines in kidney transplant recipients.

Am J Transplant 2021 Jul 31. Epub 2021 Jul 31.

Department of Medicine, Division of Infectious Diseases, University of Pittsburgh and UPMC, Pittsburgh, Pennsylvania, USA.

Mortality due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) among transplant recipients is high . In December 2020 the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna) vaccines received emergency use authorization in the United States. These mRNA vaccines administered in a two-dose series were more than 94% effective in preventing COVID-19 in clinical trials, without safety concerns identified . Read More

View Article and Full-Text PDF

Patients with suspected allergic reactions to COVID-19 vaccines can be safely revaccinated after diagnostic work-up.

Clin Transl Allergy 2021 Jul;11(5):e12044

Department of Dermatology and Allergy Center, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.

Background: When initiating the Danish vaccination program against COVID-19, the incidence of anaphylaxis was estimated to be 10 times higher compared to other virus-based vaccines. In this study, we present data on patients referred with suspected allergic reactions to COVID-19 vaccines. The main purpose of the study is to investigate the incidence and severity of the allergic reactions, and to evaluate the safety of revaccination. Read More

View Article and Full-Text PDF

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.

Nat Med 2021 Jul 30. Epub 2021 Jul 30.

Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.

CoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved for emergency use in several countries. However, its immunogenicity in immunocompromised individuals has not been well established. We initiated a prospective phase 4 controlled trial (no. Read More

View Article and Full-Text PDF

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial.

Nat Commun 2021 07 30;12(1):4636. Epub 2021 Jul 30.

The Jenner Institute, University of Oxford, Oxford, United Kingdom.

Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that causes swift outbreaks. Major concerns are the persistent and disabling polyarthralgia in infected individuals. Here we present the results from a first-in-human trial of the candidate simian adenovirus vectored vaccine ChAdOx1 Chik, expressing the CHIKV full-length structural polyprotein (Capsid, E3, E2, 6k and E1). Read More

View Article and Full-Text PDF

Guillain-Barré syndrome after COVID-19 vaccination.

BMJ Case Rep 2021 Jul 30;14(7). Epub 2021 Jul 30.

Department of Neurosciences, Mater Dei Hospital, Msida, Malta.

We report a case of Guillain-Barré syndrome (GBS) occurring soon after the first dose of Vaxzevria (previously known as COVID-19 vaccine AstraZeneca). Thus far, there has been no evidence of an increased risk of GBS resulting from either COVID-19 infection nor from COVID-19 vaccines; however, individual cases and population cohorts should be scrutinised, in order to ensure the constant evaluation of such risks. It is as yet not possible to draw conclusions about any significant association between COVID-19 vaccination and GBS. Read More

View Article and Full-Text PDF

Pertussis immunisation during pregnancy: Antibody levels and the impact of booster vaccine.

Vaccine 2021 Jul 27. Epub 2021 Jul 27.

Department of Public Health Sciences and Paediatrics, University of Turin, 5/bis, Via Santena, I-10126 Turin, Italy. Electronic address:

Pertussis (whooping cough) is a highly infectious disease caused by Bordetella pertussis. Mothers lacking adequate immunity and contracting the disease represent the biggest risk of transmission to new-borns, for which the disease is often a threat. The aim of the study was to estimate the frequency of pertussis susceptibility among pregnant women, in order to point out the need for a vaccine recall during pregnancy, and to evaluate the antibody response in already vaccinated women. Read More

View Article and Full-Text PDF

Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study.

Clin Microbiol Infect 2021 Jul 27. Epub 2021 Jul 27.

Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria hospital, via Sempreboni 5, 37024 Negrar di Valpolicella, Verona, Italy; Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

Objectives: We assessed the antibody response to BNT162b2 mRNA COVID-19 vaccine in a cohort of health care workers (HCW), comparing subjects with previous SARS-CoV-2 infection and naïve subjects.

Methods: HCW were tested at T0 (day of first dose), T1 (day of second dose), and T2 (2-3 weeks after) for IgG anti nucleocapside protein, IgM anti spike protein and IgG anti receptor binding domain (IgG-RBD-S). The antibody response was compared between 4 main groups: A) Subjects with previous infection and positive antibodies at baseline; B) subjects with same history but negative antibodies; C) subjects with no infection history but positive antibodies; D) naïve subjects. Read More

View Article and Full-Text PDF

Cellular responses at the application site of a high-density microarray patch delivering an influenza vaccine in a randomized, controlled phase I clinical trial.

PLoS One 2021 30;16(7):e0255282. Epub 2021 Jul 30.

Vaxxas Pty Ltd, Brisbane, Queensland, Australia.

Microarray patches (MAPs) have the potential to be a safer, more acceptable, easier to use and more cost-effective method for administration of vaccines when compared to the needle and syringe. Since MAPs deliver vaccine to the dermis and epidermis, a degree of local immune response at the site of application is expected. In a phase 1 clinical trial (ACTRN 12618000112268), the Vaxxas high-density MAP (HD-MAP) was used to deliver a monovalent, split inactivated influenza virus vaccine into the skin. Read More

View Article and Full-Text PDF

Efficacy of Brucella abortus S19 and RB51 vaccine strains: a systematic review and meta-analysis.

Transbound Emerg Dis 2021 Jul 30. Epub 2021 Jul 30.

Departamento de Medicina Veterinária, Faculdade de Zootecnia e Medicina Veterinária, Universidade Federal de Lavras - UFLA, Lavras, Brazil.

This systematic review and meta-analysis aimed to recalculate the efficacy of Brucella abortus S19 and RB51 vaccine strains and discuss the main variables associated with controlled trials to evaluate bovine brucellosis vaccine efficacy. The most commonly used vaccine strain was S19, at a dose of 10 colony forming units (CFU), followed by RB51 at 10 CFU. The most commonly used challenge strain was B. Read More

View Article and Full-Text PDF

Field safety experience with an autologous cancer vaccine in tumor-bearing cats: a retrospective study of 117 cases (2015-2020).

J Feline Med Surg 2021 Jul 30:1098612X211031504. Epub 2021 Jul 30.

The Office of the Vice President for Research, University of Kentucky, Lexington, KY, USA.

Objectives: The aim of this study was to determine the frequency and severity of adverse events (AEs) reported from use of an adjuvanted whole-cell autologous cancer vaccine in cats with solid tumors under field conditions.

Methods: The case accession database at Torigen Pharmaceuticals was searched to identify client-owned cats that underwent biopsy or surgical resection of their primary tumor, had histologic confirmation of neoplasia and received at least one subcutaneous dose of an adjuvanted whole-cell autologous cancer vaccine. Records were reviewed for any reported AEs. Read More

View Article and Full-Text PDF

Changes in epidemiological features of vaccine preventable infectious diseases among three eras of national vaccination strategies from 1953 to 2018 in Shanghai, China.

Lancet Reg Health West Pac 2021 Feb 23;7:100092. Epub 2021 Jan 23.

Xuhui District Center for Disease Control and Prevention, Shanghai 200237, China.

Background: Recurring outbreaks of infectious diseases highlight the importance of population vaccination strategies. We aimed to assess the impact of national vaccination strategies on vaccine-preventable infectious diseases (VPDs) in Shanghai, China and to identify vulnerable groups that may benefit from future vaccination policies.

Methods: Infectious disease data from 1953 to 2018 was obtained from Xuhui District Center for Disease Control and Prevention, Shanghai China. Read More

View Article and Full-Text PDF
February 2021

Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial.

Lancet Reg Health West Pac 2021 May 16;10:100133. Epub 2021 Apr 16.

Chinese Center for Disease Control and Prevention, Beijing, China.

Background: We assessed immunogenicity of three-dose and two-dose immunization schedules with a Sabin-strain inactivated poliovirus vaccine (sIPV) produced by one Chinese vaccine manufacturer.

Methods: This was an open label, randomized, controlled trial conducted in 16 vaccination clinics in Shandong province. Infants were allocated randomly to either a 3-dose study arm (sIPV administered at 2, 3, and 4 months of age) or a 2-dose arm (sIPV administered at 4 and 8-11 months of age). Read More

View Article and Full-Text PDF

COVID-19 vaccinations are associated with reduced fatality rates: Evidence from cross-county quasi-experiments.

J Glob Health 2021 17;11:05019. Epub 2021 Jul 17.

Research Center for Epidemic Prevention, National Yang Ming Chiao Tung University, Taipei, Taiwan.

Background: Scientists have demonstrated the efficacy of vaccines against severe acute respiratory syndrome coronavirus 2 in randomized controlled trials. However, the extent to which reductions in COVID-19 case fatality ratio (CFR) are attributable to mass vaccination in the real world remains unclear. This study evaluated the association of COVID-19 vaccine coverage with CFR on a global scale. Read More

View Article and Full-Text PDF

Prevention of vertical transmission of hepatitis B virus infection.

World J Gastroenterol 2021 Jul;27(26):4182-4193

Department Neurofarba, University of Florence, Florence 50129, Italy.

Hepatitis B virus (HBV) is the leading cause of chronic viral hepatitis. Annually, almost two million children younger than 5 years acquire the infection, mostly through vertical or horizontal transmission in early life. Vertical transmission of HBV is a high efficacy phenomenon ranging, in the absence of any preventive interventions, from 70% to 90% for hepatitis e antigen positive mothers and from 10% to 40% for hepatitis e antigen-negative mothers. Read More

View Article and Full-Text PDF

Cost of vaccine delivery strategies in low- and middle-income countries during the COVID-19 pandemic.

Vaccine 2021 Jun 29. Epub 2021 Jun 29.

Center for Health Decision Science, Harvard T.H. Chan School of Public Health, United States.

Background: The COVID-19 pandemic has disrupted immunization services critical to the prevention of vaccine-preventable diseases in many low- and middle- income countries around the world. These services will need to be modified in order to minimize COVID-19 transmission and ensure the safety of health workers and the community. Additional budget will be required to implement these modifications that ensure safe delivery. Read More

View Article and Full-Text PDF

Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions.

Vaccine 2021 Jul 26. Epub 2021 Jul 26.

Center for Vaccine Development & Global Health, 685 W. Baltimore St., University of Maryland School of Medicine, Baltimore, Maryland 21201, USA. Electronic address:

Importance: Low- and middle-income countries have a high burden of respiratory syncytial virus lower respiratory tract infections. A monoclonal antibody administered monthly is licensed to prevent these infections, but it is cost-prohibitive for most low- and middle-income countries. Long-acting monoclonal antibodies and maternal vaccines against respiratory syncytial virus are under development. Read More

View Article and Full-Text PDF

Effectiveness of a single dose of Japanese encephalitis vaccine among adults, Assam, India, 2012-2018.

Vaccine 2021 Jul 26. Epub 2021 Jul 26.

Indian Council of Medical Research, New Delhi, India.

Background: Japanese encephalitis virus (JEV) remains the major etiology of encephalitis throughout Asia. In India, the state of Assam alone contributes more than one-third of the national burden of JE. Between 2011 and 2014, a single dose of JE vaccine SA 14-14-2 (LAJEV) was administered among adults aged 15-65 years residing in Sivasagar and Dibrugarh districts of Assam, India. Read More

View Article and Full-Text PDF

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia.

J Hematol Oncol 2021 07 29;14(1):119. Epub 2021 Jul 29.

Hematology Unit, Department of Research and Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.

In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten patients with myelofibrosis compared to the 32 with essential thrombocythemia (n = 17) and polycythemia vera (n = 15) grouped together, both in terms of neutralizing anti-SARS-CoV-2 IgG titers and seroprotection rates (32.47 AU/mL vs 217.97 AU/mL, p = 0. Read More

View Article and Full-Text PDF

Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy.

Hum Vaccin Immunother 2021 Jul 30:1-3. Epub 2021 Jul 30.

Memorial Bahçelievler Hospital, Clinic of Pediatrics, İstanbul, Turkey.

Maternal vaccination with SARS-CoV-2 vaccines has not been well studied yet in terms of safety and efficacy for protecting the newborn by the placental passage of antibodies. We reported 34 years of old health care worker (HCW) without any known SARS-CoV-2 infection. She had the first dose of SARS-CoV-2 inactivated virus vaccine (CoronaVac, Sinovac Life Science Co, Ltd, Beijing, China) at a gestational age of 28 weeks. Read More

View Article and Full-Text PDF

Effect of Biomodulina-T® and VA-MENGOC-BC® on lymphocyte subpopulations in older adults.

Exp Gerontol 2021 Jul 26:111497. Epub 2021 Jul 26.

Institute of Hematology and Immunology, Immunochemistry-Immunology Department, 19th St, between 8th and 10th St, Vedado, 10400 Plaza de la Revolución, Havana, Cuba.

Introduction: The elderly population suffers from the natural process called immunosenescence, which may be related to the high mortality rates it has against the SARS-CoV2 virus, which is why therapies that improve the immune status are required. The combined treatment of the VA-MENGOC-BC® (V-BC) vaccine and the Biomodulina T® (BT) drug could achieve this purpose. This treatment could immunomodulate both the innate and adaptive branches of the immune system simultaneously. Read More

View Article and Full-Text PDF

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.

Lancet Infect Dis 2021 Jul 26. Epub 2021 Jul 26.

Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.

Background: SARS-CoV-2 has caused millions of deaths, and, since Aug 11, 2020, 20 intramuscular COVID-19 vaccines have been approved for use. We aimed to evaluate the safety and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults without COVID-19 from China.

Method: This was a randomised, single-centre, open-label, phase 1 trial done in Zhongnan Hospital (Wuhan, China), to evaluate the safety and immunogenicity of the Ad5-nCoV vaccine by aerosol inhalation in adults (≥18 years) seronegative for SARS-CoV-2. Read More

View Article and Full-Text PDF

Progress Toward Hepatitis B Control - World Health Organization European Region, 2016-2019.

MMWR Morb Mortal Wkly Rep 2021 Jul 30;70(30):1029-1035. Epub 2021 Jul 30.

In 2019, an estimated 14 million persons in the World Health Organization (WHO) European Region* (EUR) were chronically infected with hepatitis B virus (HBV), and approximately 43,000 of these persons died from complications of chronic HBV infection (1). In 2016, the WHO Regional Office for Europe set hepatitis B control program targets for 2020, including 1) ≥90% coverage with 3 doses of hepatitis B vaccine (HepB3), 2) ≥90% coverage with interventions to prevent mother-to-child transmission (MTCT) of HBV, and 3) ≤0.5% prevalence of HBV surface antigen (HBsAg) in age groups eligible for vaccination with hepatitis B vaccine (HepB) (2-4). Read More

View Article and Full-Text PDF

SARS-CoV-2 Infection in Public School District Employees Following a District-Wide Vaccination Program - Philadelphia County, Pennsylvania, March 21-April 23, 2021.

MMWR Morb Mortal Wkly Rep 2021 Jul 30;70(30):1040-1043. Epub 2021 Jul 30.

The School District of Philadelphia reopened for in-school instruction the week of March 21, 2021, and required weekly testing for SARS-CoV-2, the virus that causes COVID-19, for all employees returning to in-school responsibilities. The resumption of in-school instruction followed a mass vaccination program using the Pfizer-BioNTech 2-dose vaccine offered under a partnership between the Philadelphia Department of Public Health and Children's Hospital of Philadelphia to all 22,808 School District of Philadelphia employees during February 23-April 3, 2021.* The subsequent mandatory testing program provided an opportunity to assess the percentage of positive BinaxNow point-of-care antigen tests (Abbott Laboratories) identified among school staff members based on their self-reported vaccination status (i. Read More

View Article and Full-Text PDF

Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers.

Hum Vaccin Immunother 2021 Jul 29:1-5. Epub 2021 Jul 29.

Memorial Ataşehir Hospital, Clinic of Pediatrics, İstanbul, Turkey.

The effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected HCWs. All HCWs were immunized with two doses of CoronaVac (600 U/0. Read More

View Article and Full-Text PDF

Immunogenicity of varicella zoster vaccine in pediatric liver transplantation.

Pediatr Int 2021 Jul 29. Epub 2021 Jul 29.

Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Background: Pediatric liver transplant (LT) candidates often miss complete VZV vaccination before LT. We aimed to evaluate the immunogenicity of two doses of VZV vaccines in pediatric LT candidates younger than 2 years and its persistence of immunogenicity after LT.

Methods: Patients aged 9-24 months were enrolled before LT. Read More

View Article and Full-Text PDF

The effect of a single dose of BNT162b2 vaccine on the incidence of severe COVID-19 infection in patients on chronic hemodialysis: a single-centre study.

Clin Exp Nephrol 2021 Jul 29. Epub 2021 Jul 29.

East Suffolk & North Essex NHS Foundation Trust, Colchester General Hospital, Turner Rd., Colchester, CO4 5JL, UK.

Introduction: In this single-centre retrospective observational study, the 8-week safety and the efficiency of a single dose of BNT162b2 vaccine was studied in 83 HD patients.

Methods: All clinically stable adult ESRD patients on chronic HD for at least 4 weeks were screened for participation in the study. Exclusion criteria for enrollment in the study included a medical history of COVID-19 infection within the last 12 weeks or delivery of both vaccine doses less than 8 weeks apart from each other. Read More

View Article and Full-Text PDF

Single Replication M2SR Influenza Vaccine Induced Immune Responses Associated with Protection Against Human Challenge with Highly Drifted H3N2 Influenza Strain.

J Infect Dis 2021 Jul 29. Epub 2021 Jul 29.

FluGen, Inc., Madison, WI, USA.

Background: Current influenza vaccines are strain-specific and demonstrate low vaccine efficacy against H3N2 influenza disease, especially when vaccine is mis-matched to circulating virus. The novel influenza vaccine candidate, M2SR (M2-deficient Single Replication), induces a broad, multi-effector immune response.

Methods: A phase 2 challenge study was conducted to assess efficacy of M2SR vaccine expressing HA and NA from A/Brisbane/10/2007 (H3N2, clade 1). Read More

View Article and Full-Text PDF